MCID: GRM005
MIFTS: 54

Germ Cell Cancer

Categories: Cancer diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Germ Cell Cancer

MalaCards integrated aliases for Germ Cell Cancer:

Name: Germ Cell Cancer 12 56 15
Malignant Germ Cell Tumor 54 17
Neoplasms, Germ Cell and Embryonal 45
Malignant Tumor of the Germ Cell 12
Neoplasms Germ Cell 56
Germ Cell Neoplasm 12
Germ Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2994
MeSH 45 D009373
NCIt 51 C3708
SNOMED-CT 69 28307001
UMLS 74 C0205851

Summaries for Germ Cell Cancer

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from germ cells.

MalaCards based summary : Germ Cell Cancer, also known as malignant germ cell tumor, is related to extragonadal germ cell cancer and testicular malignant germ cell cancer. An important gene associated with Germ Cell Cancer is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and PI3K-Akt signaling pathway. The drugs Paclitaxel and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include testis, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Related Diseases for Germ Cell Cancer

Diseases related to Germ Cell Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 extragonadal germ cell cancer 34.5 AFP POU5F1
2 testicular malignant germ cell cancer 34.1 AFP ALPP
3 ovarian mixed germ cell neoplasm 34.1 AFP CGA
4 testicular germ cell cancer 34.1 ALPP AR DMRT1 ESR2 KITLG
5 pediatric ovarian germ cell tumor 32.3 ALPP ENO2
6 dysgerminoma 32.1 AFP ALPP ENO2
7 germ cell and embryonal cancer 32.1 AFP ENO2 POU5F1
8 testicular cancer 31.1 AFP ALPP AR CGA
9 testicular seminoma 30.7 AFP CGA
10 cryptorchidism, unilateral or bilateral 30.6 ALPG AR CGA
11 seminoma 30.4 AFP ALPG ALPP CGA ENO2 ESR2
12 mature teratoma 30.4 AFP KRAS POU5F1
13 teratoma 30.4 AFP CGA DMRT1 ENO2 POU5F1
14 choriocarcinoma 30.3 ALPG ALPP CGA H19
15 intratubular embryonal carcinoma 30.3 AFP POU5F1
16 malignant teratoma 30.2 AFP ENO2 POU5F1
17 embryonal carcinoma 29.8 AFP FGF4 H19 IGF2 POU5F1
18 prostate cancer 29.1 AR ENO2 ESR1 ESR2 H19 IGF2
19 breast cancer 29.0 AR CSF3 ESR1 ESR2 FGF4 H19
20 ovarian germ cell cancer 12.6
21 mixed germ cell cancer 12.5
22 mixed extragonadal germ cell cancer 12.4
23 pediatric germ cell cancer 12.4
24 retroperitoneal germ cell neoplasm 12.3
25 malignant pineal area germ cell neoplasm 12.3
26 malignant childhood germ cell neoplasm 12.2
27 fallopian tube germ cell cancer 12.2
28 malignant germ cell tumor of the cervix uteri 11.4
29 malignant cardiac germ cell tumor 11.3
30 malignant non-dysgerminomatous germ cell tumor of ovary 11.2
31 malignant germ cell tumor of the vagina 11.2
32 malignant germ cell tumor of the corpus uteri 11.2
33 malignant dysgerminomatous germ cell tumor of the ovary 11.2
34 vaginal yolk sac tumor 11.2
35 central nervous system childhood germ cell tumor 11.2
36 pediatric testicular germ cell tumor 11.2
37 childhood testicular mixed germ cell tumor 11.2
38 childhood germ cell brain tumor 11.2
39 ovarian primitive germ cell tumor 11.1
40 choriocarcinoma of ovary 11.1
41 immature teratoma of ovary 11.1
42 endodermal sinus tumor 11.1
43 germinoma 11.1
44 fallopian tube teratoma 11.1
45 extragonadal nonseminomatous germ cell tumor 11.1
46 polyembryoma 10.5 AFP CGA
47 sacrococcygeal teratoma 10.5 AFP CGA
48 mixed germ cell tumor 10.5 AFP CGA
49 central nervous system germinoma 10.5 ALPP POU5F1
50 triploidy 10.5 AFP CGA

Graphical network of the top 20 diseases related to Germ Cell Cancer:



Diseases related to Germ Cell Cancer

Symptoms & Phenotypes for Germ Cell Cancer

GenomeRNAi Phenotypes related to Germ Cell Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AFP ATF7IP CSF3 H19 IGF2 KRAS

MGI Mouse Phenotypes related to Germ Cell Cancer:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 ALPG AR CGA ENO2 ESR1 ESR2
2 endocrine/exocrine gland MP:0005379 10.25 AFP AR CGA DMRT1 ESR1 ESR2
3 mortality/aging MP:0010768 10.18 AFP ALPG AR ESR1 ESR2 FGF4
4 digestive/alimentary MP:0005381 10.14 AR ESR1 ESR2 IGF2 KITLG KRAS
5 embryo MP:0005380 10.13 ALPG AR ESR1 FGF4 IGF2 KITLG
6 integument MP:0010771 10.08 AR CSF3 ESR1 ESR2 IGF2 KITLG
7 limbs/digits/tail MP:0005371 10.06 AR ESR1 ESR2 FGF4 IGF2 KITLG
8 nervous system MP:0003631 10.06 AR CGA ENO2 ESR1 ESR2 IGF2
9 liver/biliary system MP:0005370 10.03 AFP AR ESR1 ESR2 IGF2 KITLG
10 reproductive system MP:0005389 9.97 AFP ALPG AR CGA DMRT1 ESR1
11 neoplasm MP:0002006 9.91 AFP AR ESR1 ESR2 KITLG KRAS
12 normal MP:0002873 9.86 ALPG AR ESR1 ESR2 FGF4 KRAS
13 respiratory system MP:0005388 9.56 ENO2 ESR1 ESR2 FGF4 IGF2 KRAS
14 skeleton MP:0005390 9.28 AR ESR1 ESR2 FGF4 IGF2 KITLG

Drugs & Therapeutics for Germ Cell Cancer

Drugs for Germ Cell Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
2
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
3
Bleomycin Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 11056-06-7 5360373
4
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 135968-09-1
5
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
6
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
7
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
8
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
9
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 1177-87-3
11
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 3375-50-6 598
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
13
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
14
Testosterone Approved, Experimental, Investigational Phase 2, Phase 3 58-22-0, 481-30-1 6013 10204
15
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
16
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
17
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
18
Promethazine Approved, Investigational Phase 3 60-87-7 4927
19
Histamine Approved, Investigational Phase 3 51-45-6 774
20
Cyproheptadine Approved Phase 3 129-03-3 2913
21
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 8001-79-4
22 Etoposide phosphate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
23 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
24 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
25 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
26 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
27 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
28 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
29 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Not Applicable
30 Alkylating Agents Phase 3,Phase 1,Phase 2,Not Applicable
31
Isophosphamide mustard Phase 3,Phase 1,Phase 2 0
32 BB 1101 Phase 3,Phase 1,Phase 2
33 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable
34 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2,Not Applicable
35 Liver Extracts Phase 3,Phase 2,Phase 1
36 Testosterone 17 beta-cypionate Phase 2, Phase 3
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
38 Laxatives Phase 2, Phase 3
39 Antineoplastic Agents, Hormonal Phase 2, Phase 3
40 Androgens Phase 2, Phase 3
41 Gastrointestinal Agents Phase 2, Phase 3,Phase 3
42 Cathartics Phase 2, Phase 3
43 Hormone Antagonists Phase 2, Phase 3
44 Hormones Phase 2, Phase 3
45 Castor Phase 2, Phase 3
46 Anabolic Agents Phase 2, Phase 3
47 Dermatologic Agents Phase 3,Phase 2
48 Podophyllotoxin Phase 3 518-28-5
49 Keratolytic Agents Phase 3
50 Histamine H2 Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Men With Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
2 Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle Unknown status NCT00589537 Phase 3
3 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
4 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
5 Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles Completed NCT00324298 Phase 3 cisplatin;etoposide
6 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
7 TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors Recruiting NCT02429687 Phase 3 Paclitaxel;Carboplatin;Bleomycin;Etoposide;Cisplatin
8 Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Bleomycin;Carboplatin;Cisplatin;Etoposide;Etoposide Phosphate
9 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
10 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
11 Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer Unknown status NCT02433197 Phase 1, Phase 2
12 Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
13 Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Unknown status NCT00772694 Phase 2 sorafenib
14 Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer Completed NCT00371553 Phase 2 SU011248 (Sunitinib)
15 Everolimus in Refractory Testicular Germ Cell Cancer Completed NCT01466231 Phase 2 Everolimus
16 Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Completed NCT01242631 Phase 2 Everolimus
17 Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer Completed NCT00002903 Phase 2 docetaxel
18 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
19 Avelumab in Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
20 Arsenic Trioxide in Treating Men With Germ Cell Cancer Completed NCT00036842 Phase 2 arsenic trioxide
21 Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors Completed NCT01851200 Phase 2 Brentuximab Vedotin
22 Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer Completed NCT00002943 Phase 2 carboplatin;cyclophosphamide;etoposide
23 Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin Completed NCT00611962 Phase 2 Oxaliplatin, Paclitaxel
24 Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients Completed NCT00393861 Phase 2 Bevacizumab and Oxaliplatin
25 Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors Completed NCT00002508 Phase 1, Phase 2 carboplatin;etoposide
26 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors Completed NCT00002558 Phase 1, Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
27 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
28 Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
29 Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors Completed NCT00003811 Phase 2 amifostine trihydrate;cisplatin;etoposide
30 Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors Completed NCT00002489 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;vincristine sulfate
31 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
32 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
33 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
34 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2 carboplatin;etoposide;ifosfamide;thiotepa
35 High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Completed NCT00003173 Phase 2 thiotepa
36 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
37 Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer Recruiting NCT02860819 Phase 2 Veliparib;Gemcitabine;Carboplatin
38 Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer Recruiting NCT02478502 Phase 2 cabazitaxel
39 First Line TIP in Poor Prognosis TGCTs. Recruiting NCT02414685 Phase 2 Paclitaxel;Ifosfamide;Cisplatin
40 Role of Axumin PET Scan in Germ Cell Tumor Recruiting NCT03426865 Phase 2 Axumin PET scan
41 A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent Recruiting NCT02104986 Phase 2 Velbe-Bleomycin-Cisplatin;Vepeside-ifosfamide-Cisplatin
42 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03698994 Phase 2 Ulixertinib
43 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
44 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
45 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
46 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
47 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
48 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03220035 Phase 2 Vemurafenib
49 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
50 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib

Search NIH Clinical Center for Germ Cell Cancer

Cochrane evidence based reviews: neoplasms, germ cell and embryonal

Genetic Tests for Germ Cell Cancer

Anatomical Context for Germ Cell Cancer

MalaCards organs/tissues related to Germ Cell Cancer:

42
Testis, Bone, Bone Marrow, Brain, Testes, Lymph Node, Liver

Publications for Germ Cell Cancer

Articles related to Germ Cell Cancer:

(show top 50) (show all 405)
# Title Authors Year
1
Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome? ( 30733184 )
2019
2
Re: MicroRNA-371a-3p as Informative Biomarker for the Follow-up of Testicular Germ Cell Cancer Patients. ( 30634340 )
2019
3
Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development. ( 30739914 )
2019
4
Re: Risk of Solid Cancer after Treatment of Testicular Germ Cell Cancer in the Platinum Era. ( 30759676 )
2019
5
Current pharmacotherapy for testicular germ cell cancer. ( 30849243 )
2019
6
Complex Polygenic Nature of Testicular Germ Cell Cancer Suggests Multifactorial Aetiology. ( 29530636 )
2018
7
A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study. ( 29587278 )
2018
8
Is the FSHR 2039A>G variant associated with susceptibility to testicular germ cell cancer? ( 29179257 )
2018
9
Improved survival in metastatic germ-cell cancer. ( 29161363 )
2018
10
Long-term toxicity of the treatment for germ cell-cancer. A review. ( 29279100 )
2018
11
Therapeutic approaches for refractory germ cell cancer. ( 29516750 )
2018
12
High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. ( 29721375 )
2018
13
Testis-Sparing Surgery in Patients with Germ Cell Cancer: Indications and Clinical Outcome. ( 29763922 )
2018
14
Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer. ( 29957683 )
2018
15
Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. ( 29989856 )
2018
16
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. ( 30113631 )
2018
17
Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer. ( 30115544 )
2018
18
Management of Refractory Germ Cell Cancer. ( 30231348 )
2018
19
Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. ( 30285559 )
2018
20
Palliative treatment of germ cell cancer. ( 30415106 )
2018
21
High-Dose Chemotherapy in Relapsed or Refractory Metastatic Germ-Cell Cancer: The Scotland Experience. ( 30563754 )
2018
22
Prognostic Impact of Lymphadenectomy in Different Stages of Malignant Germ Cell Tumor of the Ovary Based on Propensity Score Matching. ( 30569854 )
2018
23
microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. ( 28612337 )
2017
24
Cisplatin-related Cerebral Infarction in Testicular Germ Cell Cancer: Short Report of Three Cases and P in testicular germ cell cancer: Short report of three cases and pathomechanism. ( 27923208 )
2017
25
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. ( 28202195 )
2017
26
Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality. ( 28591464 )
2017
27
Animacroxam, a novel dual-mode compound targeting histone deacetylases and cytoskeletal integrity of testicular germ cell cancer cells. ( 28838999 )
2017
28
Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study. ( 27649970 )
2017
29
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how. ( 27678272 )
2017
30
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients. ( 28122896 )
2017
31
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. ( 28262583 )
2017
32
Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. ( 28281024 )
2017
33
Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. ( 28591197 )
2017
34
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. ( 28753776 )
2017
35
Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. ( 28753801 )
2017
36
No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer. ( 28866371 )
2017
37
Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). ( 28938535 )
2017
38
Re: Second Malignant Neoplasms and Cause of Death in Patients with Germ Cell Cancer: A Danish Nationwide Cohort Study. ( 29059778 )
2017
39
A Brief Review of the Link between Environment and Male Reproductive Health: Lessons from Studies of Testicular Germ Cell Cancer. ( 26871895 )
2016
40
Effectiveness of an individualized program of muscular strength and endurance with aerobic training for improving germ cell cancer-related fatigue in men undergoing chemotherapy: EFICATEST study protocol for a randomized controlled trial. ( 26732120 )
2016
41
Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin. ( 26903578 )
2016
42
High Rates of Thromboembolic Events in Patients with Germ Cell Cancer Undergoing Cisplatin-Based Polychemotherapy. ( 27074038 )
2016
43
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care-Registry data from an outcomes research project of the German Testicular Cancer Study Group. ( 26699830 )
2016
44
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. ( 27821802 )
2016
45
Muscle satellite cell content and mRNA signaling in germ cell cancer patients - effects of chemotherapy and resistance training. ( 27218150 )
2016
46
Androgen receptor gene CAG and GGN repeat lengths as predictors of recovery of spermatogenesis following testicular germ cell cancer treatment. ( 27873769 )
2016
47
Elucidating human male germ cell development by studying germ cell cancer. ( 27512122 )
2016
48
Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. ( 27711914 )
2016
49
The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer. ( 27732956 )
2016
50
Validation of a prediction model for avoiding post-chemotherapy retroperitoneal lymphadenectomy in patients with metastatic nonseminomatous germ cell cancer. ( 27878048 )
2016

Variations for Germ Cell Cancer

Expression for Germ Cell Cancer

Search GEO for disease gene expression data for Germ Cell Cancer.

Pathways for Germ Cell Cancer

Pathways related to Germ Cell Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 ESR1 ESR2 FGF4 IGF2 KITLG KRAS
2
Show member pathways
12.75 CSF3 FGF4 IGF2 KITLG KRAS TERT
3
Show member pathways
12.47 ESR1 ESR2 FGF4 IGF2 KRAS TERT
4 12.28 AR ESR1 ESR2 FGF4 IGF2 KITLG
5
Show member pathways
12.26 CGA ESR1 ESR2 KRAS
6
Show member pathways
12.01 FGF4 IGF2 KITLG KRAS TERT
7
Show member pathways
11.63 AR ESR1 ESR2
8 11.55 AR FGF4 TERT
9 11.54 AR ESR1 ESR2 KRAS
10 11.53 FGF4 IGF2 KITLG KRAS
11 11.22 AFP ALPP FGF4 KITLG POU5F1 TERT
12 10.78 FGF4 POU5F1
13 10.73 ALPG ALPP
14 10.69 ESR1 ESR2 KRAS
15 9.97 ESR1 ESR2

GO Terms for Germ Cell Cancer

Biological processes related to Germ Cell Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.87 AR ATF7IP DMRT1 ESR1 ESR2 IGF2
2 regulation of signaling receptor activity GO:0010469 9.77 CGA CSF3 FGF4 IGF2 KITLG
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.76 AR CGA CSF3 DMRT1 ESR1 FGF4
4 phosphatidylinositol phosphorylation GO:0046854 9.69 ESR1 FGF4 KITLG
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.67 CSF3 ESR1 ESR2
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 CSF3 IGF2 KITLG
7 male gonad development GO:0008584 9.56 AR DMRT1 ESR1 KITLG
8 mammary gland alveolus development GO:0060749 9.48 AR ESR1
9 striated muscle cell differentiation GO:0051146 9.46 IGF2 KRAS
10 transcription, DNA-templated GO:0006351 9.4 AR ESR1
11 positive regulation of protein kinase B signaling GO:0051897 9.35 CSF3 ESR1 FGF4 IGF2 KITLG
12 positive regulation of cell proliferation GO:0008284 9.17 AR CGA CSF3 FGF4 IGF2 KITLG

Molecular functions related to Germ Cell Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 CSF3 FGF4 IGF2 KITLG
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 ESR1 FGF4 KITLG
3 steroid hormone receptor activity GO:0003707 9.54 AR ESR1 ESR2
4 alkaline phosphatase activity GO:0004035 9.4 ALPG ALPP
5 nuclear receptor activity GO:0004879 9.33 AR ESR1 ESR2
6 estrogen receptor activity GO:0030284 9.26 ESR1 ESR2
7 estrogen response element binding GO:0034056 8.96 ESR1 ESR2
8 steroid binding GO:0005496 8.8 AR ESR1 ESR2

Sources for Germ Cell Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....